Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MQX-503 in Raynaud's Phenomenon
NCT00266669Phase 3Completed
- Sponsor
- MediQuest Therapeutics
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in Raynaud's phenomenon (RP) comparing MQX-503 with Placebo (2 arms). Primary endpoints: Raynaud's Assessment Score, Number of Raynaud's events and 3 more. Started Dec 2005; status: completed.
02
Drugs
MQX-503
03
Conditions
Raynaud's phenomenon (RP)
Beyond the preview
Go deeper on NCT00266669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00266669.